FDA guidance
Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is…
FDA guidance · Draft · issued Jan 7, 2025
Key facts
| Title | Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway |
|---|---|
| Status | Draft |
| Issue date | Jan 7, 2025 |
| Center | Office of the Commissioner |
| Issuing office | Oncology Center of Excellence |
| Communication type | Guidance Document |
| Regulated product | Biologics, Drugs |
| Docket number | FDA-2024-D-3334 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents